Immune evasion strategies of flaviviruses

Vaccine

Volumn 31, Issue 3, 2013, Pages 461-471

  Ye, Jing ^a   Zhu, Bibo ^a   Fu, Zhen F ^a,b   Chen, Huanchun ^a   Cao, Shengbo ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adaptive immunity; Flavivirus; Immune evasion; Innate immunity

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGENIC VARIATION; APOPTOSIS; B LYMPHOCYTE; CELLULAR IMMUNITY; FLAVIVIRUS; FLAVIVIRUS INFECTION; GENETIC TRANSCRIPTION; GENOME; HOST; HOST CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOMODULATION; INNATE IMMUNITY; LIFE CYCLE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; FLAVIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION;

EID: 84871654982     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.015     Document Type: Review

References (158)

1. Gubler D., Kuno G., Markoff L. Flaviviruses 2007, 1153-1253. Lippincott William & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
2. Gould E.A., Solomon T. Pathogenic flaviviruses. Lancet 2008, 371:500-509.
3. Mackenzie J.S., Gubler D.J., Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004, 10:S98-S109.
4. World Health Organization [internet]. Dengue fact sheet [cited January 2012]. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/index.html.
5. World Health Organization [internet]. Manual for the laboratory diagnosis of Japanese encephalitis virus infection; March 2007. Available from: http://www.who.int/immunization%20monitoring/Manual_lab_diagnosis%20_JE.pdf.
6. World Health Organization [internet]. Yellow fever fact sheet [cited January 2011]. Available from: http://www.who.int/mediacentre/factsheets/fs100/en/index.html.
7. Murray K.O., Mertens E., Despres P. West Nile virus and its emergence in the United States of America. Vet Res 2010, 41(6):67.
8. Bressanelli S., Stiasny K., Allison S.L., Stura E.A., Duquerroy S., Lescar J., et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 2004, 23:728-738.
9. Lindenbach B.D., Thiel H.J., Rice C.M. Flaviviridae: the viruses and their replication 2007, Lippincott William & Wilkins, Philadelphia, USA, p. 1101-52.
10. Tassaneetrithep B., Burgess T.H., Granelli-Piperno A., Trumpfheller C., Finke J., Sun W., et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003, 197(April (7)):823-829.
11. Marianneau P., Steffan A.M., Royer C., Drouet M.T., Jaeck D., Kirn A., et al. Infection of primary cultures of human Kupffer cells by dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol 1999, 73:5201-5206.
12. Barba-Spaeth G., Longman R.S., Albert M.L., Rice C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 2005, 202:1179-1184.
13. Lozach P.Y., Burleigh L., Staropoli I., Navarro-Sanchez E., Harriague J., Virelizier J.L., et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem 2005, 280:23698-23708.
14. Krishnan M.N., Sukumaran B., Pal U., Agaisse H., Murray J.L., Hodge T.W., et al. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol 2007, 81:4881-4885.
15. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2A resolution. Nature 1995, 25:291-298.
16. Mackenzie J. Wrapping things up about virus RNA replication. Traffic 2005, 6:967-977.
17. Salonen A., Ahola T., Kääriäinen L. Viral RNA replication in association with cellular membranes. Curr Top Microbiol Immunol 2005, 285:139-173.
18. Welsch S., Miller S., Romero-Brey I. Composition and threedimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 2009, 23:365-375.
19. Li L., Lok S.M., Yu I.M., Zhang Y., Kuhn R.J., Chen J., et al. The flavivirus precursor membrane envelope protein complex: structure and maturation. Science 2008, 319:1830-1834.
20. Mukhopadhyay S., Kuhn R.J., Rossmann M.G. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005, 3:13-22.
21. Yu L., Nomaguchi M., Padmanabhan R., Markoff L. Specific requirements for elements of the 5' and 3' terminal regions in flavivirus RNA synthesis and viral replication. Virology 2008, 374:170-185.
22. Heinz F.X., Auer G., Stiasny K., Holzmann H., Mandl C., Guirakhoo F., et al. The interactions of the flavivirus envelope proteins: implications for virus entry and release. Arch Virol Suppl 1994, 9:339-348.
23. King N.J., Getts D.R., Getts M.T., Rana S., Shrestha B., Kesson A.M. Immunopathology of flavivirus infections. Immunol Cell Biol 2007, 85:33-42.
24. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001, 14(4):778-809.
25. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47.
26. Diamond M.S., Roberts T.G., Edgil D., Lu B., Ernst J., Harris E. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 2000, 74(11):4957-4966.
27. Anderson J.F., Rahal J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002, 8(1):107-108.
28. Best S.M., Morris K.L., Shannon J.G., Robertson S.J., Mitzel D.N., Park G.S., et al. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol 2005, 79(20):12828-12839.
29. Lin R.J., Liao C.L., Lin E., Lin Y.L. Blocking of the alpha interferoninduced Jak-Stat signaling pathway by Japanese encephalitis virus. J Virol 2004, 78(17):9285-9294.
30. Samuel M.A., Diamond M.S. Type I IFN protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 2005, 79(21):13350-13361.
31. Samuel M.A., Whitby K., Keller B.C., Marri A., Barchet W., Williams B.R., et al. PKR and RNAse L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 2006, 80(14):7009-7019.
32. Crance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003, 58(1):73-79.
33. Solomon T., Dung N.M., Wills B., Kneen R., Gainsborough M., Diet T.V., et al. Interferon alfa-2a in Japanese encephalitis: a randomized double-blind placebo-controlled trial. Lancet 2003, 361(9360):821-826.
34. Rahal J.J., Anderson J., Rosenberg C., Reagan T., Thompson L.L. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 2004, 190(6):1084-1087.
35. Chan-Tack K.M., Forrest G. Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flacid paralysis. Scand J Infect Dis 2005, 37(11-12):944-946.
36. Kalil A.C., Devetten M.P., Singh S., Lesiak B., Poage D.P., Bargenquast K., et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis 2005, 40(5):764-766.
37. Daffis S., Samuel M.A., Suthar M.S., Gale M., Diamond M.S. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008, 82(21):10349-10358.
38. Daffis S., Samuel M.A., Suthar M.S., Keller B.C., Gale M., Diamond M.S. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol 2008, 82(17):8465-8475.
39. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004, 10(12):1366-1373.
40. Wang J.P., Liu P., Latz E., Golenbock D.T., Finberg R.W., Libraty D.H. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol 2006, 177(10):7114-7121.
41. Tsai Y.T., Chang S.Y., Lee C.N., Kao C.L. Human TLR3 recognizes dengue virus and modulates viral replication in vitro. Cell Microbiol 2009, 11:604-615.
42. Fredericksen B.L., Gale M. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. J Virol 2006, 80(6):2913-2923.
43. Fredericksen B.L., Keller B.C., Fornek J., Katze M.G., Gale M. Establishment and maintenance of the innate antiviral response to West Nile virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008, 82(2):609-616.
44. Fredericksen B.L., Smith M., Katze M.G., Shi P.Y., Gale M. The host response to West Nile virus infection limits spread through the activation of the interferon regulatory factor 3 pathway. J Virol 2004, 78(14):7737-7747.
45. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441(7089):101-105.
46. Chang T.H., Liao C.L., Lin Y.L. Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation. Microbes Infect 2006, 8(1):157-171.
47. Fredericksen B.L., Gale M. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. J Virol 2006, 80:2913-2923.
48. Overby A.K., Popov V.L., Niedrig M., Weber F. Tick-borne encephalitis virus delays interferon induction and hides its double-stranded RNA in intracellular membrane vesicles. J Virol 2010, 84(17):8470-8483.
49. Espada-Murao L.A., Morita K. Delayed cytosolic exposure of Japanese encephalitis virus double-stranded RNA impedes interferon activation and enhances viral dissemination in porcine cells. J Virol 2011, 85(13):6736-6749.
50. Wilson J.R., de Sessions P.F., Leon M.A., Scholle F. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J Virol 2008, 82(17):8262-8271.
51. Baronti C., Sire J., de Lamballerie X., Quérat G. Nonstructural NS1 proteins of several mosquito-borne flavivirus do not inhibit TLR3 signaling. Virology 2010, 404(2):319-330.
52. Liu W.J., Chen H.B., Wang X.J., Huang H., Khromykh A.A. Analysis of adaptive mutations in kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J Virol 2004, 78(22):12225-12235.
53. Liu W.J., Wang X.J., Clark D.C., Lobigs M., Hall R.A., Khromykh A.A. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol 2006, 80(5):2396-2404.
54. Arjona A., Ledizet M., Anthony K., Bonafé N., Modis Y., Town T., et al. West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J Immunol 2007, 179(12):8403-8409.
55. Takaoka A., Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006, 8:907-922.
56. Muñoz-Jordan J.L., Sánchez-Burgos G.G., Laurent-Rolle M., García-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci USA 2003, 100:14333-14338.
57. Liu W.J., Wang X.J., Mokhonov V.V., Shi P.Y., Randall R., Khromykh A.A. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J Virol 2005, 79:1934-1942.
58. Muñoz-Jordán J.L., Laurent-Rolle M., Ashour J., Martínez-Sobrido L., Ashok M., Lipkin W.I., et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005, 79:8004-8013.
59. Guo J.T., Hayashi J., Seeger C. West Nile virus inhibits the signal transduction pathway of alpha interferon. J Virol 2005, 79:1343-1350.
60. Best S.M., Morris K.L., Shannon J.G., Robertson S.J., Mitzel D.N., Park G.S., et al. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol 2005, 79:12828-12839.
61. Werme K., Wigerius M., Johansson M. Tick-borne encephalitis virus NS5 associates with membrane protein scribble and impairs interferon-stimulated JAK-STAT signalling. Cell Microbiol 2008, 10(3):696-712.
62. Lin R.J., Chang B.L., Yu H.P., Liao C.L., Lin Y.L. Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. J Virol 2006, 80(12):5908-5918.
63. Jones M., Davidson A., Hibbert L., Gruenwald P., Schlaak J., Ball S., et al. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 2005, 79:5414-5420.
64. Ashour J., Laurent-Rolle M., Shi P.Y., García-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol 2009, 83(11):5408-5418.
65. Ho L.J., Hung L.F., Weng C.Y., Wu W.L., Chou P., Lin Y.L., et al. Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via downregulating Tyk2-STAT signaling in the human dendritic cell. J Immunol 2005, 174:8163-8172.
66. Lin R.J., Liao C.L., Lin E., Lin Y.L. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J Virol 2004, 78:9285-9294.
67. Mackenzie J.M., Khromykh A.A., Parton R.G. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe 2007, 2(4):229-239.
68. Evans J.D., Crown R.A., Sohn J.A., Seeger C. West Nile virus infection induces depletion of IFNAR1 protein levels. Viral Immunol 2011, 24(4):253-263.
69. Jiang D., Guo H., Xu C., Chang J., Gu B., Wang L., et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008, 82(4):1665-1678.
70. Sumpter R., Loo Y.M., Foy E., Li K., Yoneyama M., Fujita T., et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005, 79:2689-2699.
71. Terenzi F., Hui D.J., Merrick W.C., Sen G.C. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J Biol Chem 2006, 281:34064-34071.
72. Hui D.J., Terenzi F., Merrick W.C., Sen G.C. Mouse p56 blocks a distinct function of eukaryotic initiation factor 3 in translation initiation. J Biol Chem 2005, 280:3433-3440.
73. Daffis S., Szretter K.J., Schriewer J., Li J., Youn S., Errett J., et al. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010, 2468(7322):452-456.
74. Szretter K.J., Daniels B.P., Cho H., Gainey M.D., Yokoyama W.M., Gale M., et al. 2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog 2012, 8(May (5)):e1002698. [Epub 2012 May 10].
75. Hoenen A., Liu W., Kochs G., Khromykh A.A., Mackenzie J.M. West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein. J Gen Virol 2007, 88(Pt 11):3013-3017.
76. Lin K.C., Chang H.L., Chang R.Y. Accumulation of a 3'-terminal genome fragment in Japanese encephalitis virus-infected mammalian and mosquito cells. J Virol 2004, 78:5133-5138.
77. Pijlman G.P., Funk A., Kondratieva N., Leung J., Torres S., van der Aa L., et al. A highly structured, nuclease-resistant, noncoding RNA produced by flaviviruses is required for pathogenicity. Cell Host Microbe 2008, 4(6):579-591.
78. Schuessler A., Funk A., Lazear H.M., Cooper D.A., Torres S., Daffis S., et al. West Nile virus non-coding subgenomic RNA contributes to viral evasion of type I interferon-mediated antiviral response. J Virol 2012, 29.
79. Morgan B.P., Marchbank K.J., Longhi M.P., Harris C.L., Gallimore A.M. Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 2005, 97(2):171-179.
80. Chung K.M., Liszewski M.K., Nybakken G., Davis A.E., Townsend R.R., Fremont D.H., et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci USA 2006, 103(50):19111-19116.
81. Avirutnan P., Punyadee N., Noisakran S., Komoltri C., Thiemmeca S., Auethavornanan K., et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193(8):1078-1088.
82. Kurosu T., Chaichana P., Yamate M., Anantapreecha S., Ikuta K. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. Biochem Biophys Res Commun 2007, 362(4):1051-1056.
83. Avirutnan P., Fuchs A., Hauhart R.E., Somnuke P., Youn S., Diamond M.S., et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010, 207(4):793-806.
84. Avirutnan P., Hauhart R.E., Somnuke P., Blom A.M., Diamond M.S., Atkinson J.P. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol 2011, 187(1):424-433.
85. Lanier L.L. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008, 8:259-268.
86. Azeredo E.L., De Oliveira-Pinto L.M., Zagne S.M., Cerqueira D.I., Nogueira R.M., Kubelka C.F. NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin Exp Immunol 2006, 143:345-356.
87. Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 2004, 78:2701-2710.
88. Shrestha B., Samuel M.A., Diamond M.S. CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol 2006, 80:119-129.
89. Lopez-Botet M., Bellon T. Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol 1999, 11:301-307.
90. Tormo J., Natarajan K., Margulies D.H., Mariuzza R.A. Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature 1999, 402:623-631.
91. Allan D.S., McMichael A.J., Braud V.M. The ILT family of leukocyte receptors. Immunobiology 2000, 202:34-41.
92. Mullbacher A., Lobigs M. Up-regulation of MHC class I by flavivirus-induced peptide translocation into the endoplasmic reticulum. Immunity 1995, 3:207-214.
93. Cheng Y., King N.J., Kesson A.M. Major histocompatibility complex class I (MHC-I) induction by West Nile virus: involvement of 2 signaling pathways in MHC-I up-regulation. J Infect Dis 2004, 189:658-668.
94. Lobigs M., Mullbacher A., Lee E. Evidence that a mechanism for efficient flavivirus budding upregulates MHC class I. Immunol Cell Biol 2004, 82:184-188.
95. Hershkovitz O., Zilka A., Bar-Ilan A., Abutbul S., Davidson A., Mazzon M., et al. Dengue virus replicon expressing the nonstructural proteins suffices to enhance membrane expression of HLA class I and inhibit lysis by human NK cells. J Virol 2008, 82(15):7666-7676.
96. Desprès P., Flamand M., Ceccaldi P.E., Deubel V. Human isolates of dengue type 1 virus induce apoptosis in mouse neuroblastoma cells. J Virol 1996, 70:4090-4096.
97. Liao C.L., Lin Y.L., Wang J.J., Huang Y.L., Yeh C.T., Ma S.H., et al. Effect of enforced expression of human bcl-2 on Japanese encephalitis virus-induced apoptosis in cultured cells. J Virol 1997, 71:5963-5971.
98. Parquet M.C., Kumatori A., Hasebe F., Morita K., Igarashi A. West Nile virus-induced bax-dependent apoptosis. FEBS Lett 2001, 500:17-24.
99. Courageot M.P., Catteau A., Desprès P. Mechanisms of dengue virus-induced cell death. Adv Virus Res 2003, 60:157-186.
100. Jan J.T., Chen B.H., Ma S.H., Liu C.I., Tsai H.P., Wu H.C., et al. Potential dengue virus-triggered apoptotic pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and NF-kappaB are sequentially involved. J Virol 2000, 74:8680-8691.
101. Su H.L., Liao C.L., Lin Y.L. Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. J Virol 2002, 76:4162-4171.
102. Medigeshi G.R., Lancaster A.M., Hirsch A.J., Briese T., Lipkin W.I., Defilippis V., et al. West Nile virus infection activates the unfolded protein response, leading to CHOP induction and apoptosis. J Virol 2007, 81(20):10849-10860.
103. Chu J.J., Ng M.L. The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J Gen Virol 2003, 84:3305-3314.
104. Lee C.J., Liao C.L., Lin Y.L. Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection. J Virol 2005, 79(13):8388-8399.
105. Diamond M.S., Shrestha B., Marri A., Mahan D., Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003, 77:2578-2586.
106. Heinz F.X., Berger R., Tuma W., Kunz C. A topological and functional model of epitopes on the structural glycoprotein of tickborne encephalitis virus defined by monoclonal antibodies. Virology 1983, 126:525-537.
107. Kaufman B.M., Summers P.L., Dubois D.R., Cohen W.H., Gentry M.K., Timchak R.L., et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1989, 41:576-580.
108. Kimura-Kuroda J., Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988, 141:3606-3610.
109. Schlesinger J.J., Chapman S., Neutralizing F (ab') 2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol 1995, 76:217-220.
110. Charlier N., Leyssen P., Paeshuyse J., Drosten C., Schmitz H., Van Lommel A., et al. Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. J Gen Virol 2002, 83:1887-1896.
111. Halevy M., Akov Y., Ben-Nathan D., Kobiler D., Lachmi B., Lustig S. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch Virol 1994, 137:355-370.
112. Falgout B., Bray M., Schlesinger J.J., Lai C.J. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol 1990, 64:4356-4363.
113. Schlesinger J.J., Brandriss M.W., Cropp C.B., Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol 1986, 60:1153-1155.
114. Chung K.M., Nybakken G.E., Thompson B.S., Engle M.J., Marri A., Fremont D.H., et al. Antibodies against West Nile virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 2006, 80:1340-1351.
115. Jacobs S.C., Stephenson J.R., Wilkinson G.W. High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol 1992, 66:2086-2095.
116. Beasley D.W., Barrett A.D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 2002, 76:13097-13100.
117. Jennings A.D., Gibson C.A., Miller B.R., Mathews J.H., Mitchell C.J., Roehrig J.T., et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 1994, 169:512-518.
118. Lin B., Parrish C.R., Murray J.M., Wright P.J. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 1994, 202:885-890.
119. Lok S.M., Ng M.L., Aaskov J. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J Med Virol 2001, 65:315-323.
120. Sapkal G.N., Harini S., Ayachit V.M., Fulmali P.V., Mahamuni S.A., Bondre V.P., et al. Neutralization escape variant of West Nile virus associated with altered peripheral pathogenicity and differential cytokine profile. Virus Res 2011, 158(1-2):130-139.
121. Chua S.K., Selvanesan S., Sivalingam B., Chem Y.K., Norizah I., Zuridah H., et al. Isolation of monoclonal antibodies escape variant of dengue virus serotype 1. Singapore Med J 2006, 47(11):940-946.
122. Hawkes R.A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci 1964, 42:465-482.
123. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
124. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003, 60:421-467.
125. Ubol S., Phuklia W., Kalayanarooj S., Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 2010, 201(6):923-935.
126. Chareonsirisuthigul T., Kalayanarooj S., Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 2007, 88:365-375.
127. Modhiran N., Kalayanarooj S., Ubol S. Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis 2010, 4(12):e924.
128. van der Schaar H.M., Rust M.J., Waarts B.L., van der Ende-Metselaar H., Kuhn R.J., Wilschut J., et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 2007, 81:12019-12028.
129. Zybert I.A., van der Ende-Metselaar H., Wilschut J., Smit J.M. Functional importance of dengue virus maturation: infectious properties of immature virions. J Gen Virol 2008, 89:3047-3051.
130. Moesker B., Rodenhuis-Zybert I.A., Meijerhof T., Wilschut J., Smit J.M. Characterization of the functional requirements of West Nile virus membrane fusion. J Gen Virol 2010, 91:389-393.
131. Keelapang P., Sriburi R., Supasa S., Panyadee N., Songjaeng A., Jairungsri A., et al. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J Virol 2004, 78:2367-2381.
132. Junjhon J., Lausumpao M., Supasa S., Noisakran S., Songjaeng A., Saraithong P., et al. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J Virol 2008, 82:10776-10791.
133. Nelson S., Jost C.A., Xu Q., Ess J., Martin J.E., Oliphant T., et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 2008, 4(5):e1000060.
134. Rodenhuis-Zybert I.A., van der Schaar H.M., da Silva Voorham J.M., van der Ende-Metselaar H., Lei H.Y., Wilschut J., et al. Immature dengue virus: a veiled pathogen?. PLoS Pathog 2010, 6:e1000718.
135. Junjhon J., Edwards T.J., Utaipat U., Bowman V.D., Holdaway H.A., Zhang W., et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol 2010, 84:8353-8358.
136. Huang K.J., Yang Y.C., Lin Y.S., Huang J.H., Liu H.S., Yeh T.M., et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 2006, 176:2825-2832.
137. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
138. Freigang S., Probst H.C., Van Den Broek M. DC infection promotes antiviral CTL priming: the " Winkelried" strategy. Trends Immunol 2005, 26:13-18.
139. Kawai T., Akira S. Innate immune recognition of viral infection. Nat Immunol 2006, 7:131-137.
140. Takeuchi O., Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008, 20:17-22.
141. Balkow S., Krux F., Loser K., Becker J.U., Grabbe S., Dittmer U. Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naïve T cells, and favors expansion of regulatory T cells. Blood 2007, 110:3949-3958.
142. Moutaftsi M., Mehl A.M., Borysiewicz L.K., Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002, 99:2913-2921.
143. Knight S.C., Patterson S. Bone marrow-derived dendritic cells, infection with human immunodeficient immunodeficiency virus, and immunopathology. Annu Rev Immunol 1997, 15:593-615.
144. Navarro-Sanchez E., Altmeyer R., Amara A., Schwartz O., Fieschi F., Virelizier J.L., et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 2003, 4:723-728.
145. Tassaneetrithep B., Burgess T.H., Granelli-Piperno A., Trumpfheller C., Finke J., Sun W., et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003, 197:823-829.
146. Lin G., Simmons G., Pohlmann S., Baribaud F., Ni H., Leslie G.J., et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol 2003, 77:1337-1346.
147. Davis C.W., Nguyen H.Y., Hanna S.L., Sánchez M.D., Doms R.W., Pierson T.C. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 2006, 80(February (3)):1290-1301.
148. Palmer D.R., Sun P., Celluzzi C., Bisbing J., Pang S., Sun W., et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 2005, 79:2432-2439.
149. Aleyas A.G., George J.A., Han Y.W., Rahman M.M., Kim S.J., Han S.B., et al. Functional modulation of dendritic cells and macrophages by Japanese encephalitis virus through MyD88 adaptor moleculedependent and -independent pathways. J Immunol 2009, 183:2462-2474.
150. Chase A.J., Medina F.A., Muñoz-Jordán J.L. Impairment of CD4+ T cell polarization by dengue virus-infected dendritic cells. J Infect Dis 2011, 203(12):1763-1774.
151. Aleyas A.G., Han Y.W., George J.A., Kim B., Kim K., Lee C.K., et al. Multifront assault on antigen presentation by Japanese encephalitis virus subverts CD8+ T cell responses. J Immunol 2010, 185(3):1429-1441.
152. Cao S., Li Y., Ye J., Yang X., Chen L., Liu X., et al. Japanese encephalitis virus wild strain infection suppresses dendritic cells maturation and function, and causes the expansion of regulatory T cells. Virol J 2011, 8:39.
153. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001, 15:883-895.
154. Bashyam H.S., Green S., Rothman A.L. Dengue virus-reactive CD81 T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 2006, 176:2817-2824.
155. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003, 9(7):921-927.
156. Jerzak G., Bernard K.A., Kramer L.D., Ebel G.D. Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J Gen Virol 2005, 86(Pt 8):2175-2183.
157. Jerzak G.V., Brown I., Shi P.Y., Kramer L.D., Ebel G.D. Genetic diversity and purifying selection in West Nile virus populations are maintained during host switching. Virology 2008, 374(2):256-260.
158. Diamond M.S. Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. J Interferon Cytokine Res 2009, 29(9):521-530.